Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
29.06
+0.86 (3.05%)
At close: Apr 14, 2026, 4:00 PM EDT
29.20
+0.14 (0.48%)
After-hours: Apr 14, 2026, 5:11 PM EDT
Genmab Employees
Genmab had 2,973 employees as of December 31, 2025. The number of employees increased by 339 or 12.87% compared to the previous year.
Employees
2,973
Change
339
Growth
12.87%
Revenue / Employee
$1,251,261
Profits / Employee
$323,915
Market Cap
17.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,973 | 339 | 12.87% |
| Sep 30, 2025 | 2,681 | 46 | 1.75% |
| Jun 30, 2025 | 2,639 | 113 | 4.47% |
| Mar 31, 2025 | 2,638 | 352 | 15.40% |
| Dec 31, 2024 | 2,634 | 430 | 19.51% |
| Sep 30, 2024 | 2,635 | 503 | 23.59% |
| Jun 30, 2024 | 2,526 | 511 | 25.36% |
| Mar 31, 2024 | 2,286 | 440 | 23.84% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Sep 30, 2023 | 2,132 | 572 | 36.67% |
| Jun 30, 2023 | 2,015 | 570 | 39.45% |
| Mar 31, 2023 | 1,846 | 537 | 41.02% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Sep 30, 2022 | 1,560 | 424 | 37.32% |
| Jun 30, 2022 | 1,445 | 416 | 40.43% |
| Mar 31, 2022 | 1,309 | 438 | 50.29% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Sep 30, 2021 | 1,136 | 424 | 59.55% |
| Jun 30, 2021 | 1,029 | 393 | 61.79% |
| Mar 31, 2021 | 871 | 292 | 50.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Madrigal Pharmaceuticals | 915 |
| Revolution Medicines | 883 |
GMAB News
- 13 hours ago - Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln - Nasdaq
- 16 hours ago - Major Shareholder Announcement - GlobeNewsWire
- 20 hours ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 - GlobeNewsWire
- 1 day ago - Genmab (GMAB) Unveils Encouraging Data on New Ovarian Cancer Treatment - GuruFocus
- 1 day ago - Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer - Finanz Nachrichten
- 1 day ago - Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer - GlobeNewsWire
- 1 day ago - Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer - Business Wire
- 13 days ago - Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire